Therapeutic Options for the Treatment of Gram-Positive Infections

  • A. R. De Gaudio
Conference paper
Part of the Topics in Anaesthesia and Critical Care book series (TIACC)


The hospital intensive care unit (ICU) has been characterized as a breeding ground for antibiotic resistance. During the last decade, intensive care specialists have had to cope with increasingly resistant gram-positive pathogens. This evolving problem is related to: (a) the high proportion of neutropenic and immunocompromised patients; (b) the use of indwelling vascular access devices, and (c) the large use of drugs with activity directed against gram-negative bacilli.


Nosocomial Pneumonia Moraxella Catarrhalis Skin Structure Infection Hospital Intensive Care Unit Glycopeptide Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Michel M, Gutmann L (1997) Methicillin-resistant Staphylococus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 349: 1901–1906Google Scholar
  2. 2.
    Centers for Disease Control and Prevention (1993) 1989–1993. Nosocomial enterococci resistant to vancomycin. MMWR 42: 597–599Google Scholar
  3. 3.
    Hiramatsu K, Hanaki H, Ino T et al (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40: 135–136CrossRefGoogle Scholar
  4. 4.
    Smith TL, Pearson ML, Wilcox KR et al (1999) Emergence of vancomycin resistence in Staphylococcus aureus. N Eng1 J Med 340: 493–501CrossRefGoogle Scholar
  5. 5.
    Ackerman BH, Vannier AM, Eudy EB (1992) Analysis of vancomycin time-kill studies with Staphylococcus species by using stripping programs to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 36: 1766–1769PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Di Filippo A, De Gaudio AR, Novelli A et al (1998) Continuous infusion of vancomycin in methicillin-resistant Staphylococcus infection. Chemotherapy 44: 63–68PubMedCrossRefGoogle Scholar
  7. 7.
    Charbonnau P, Harding I,Garaud JJ et al (1994) Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Intensive Care Med 20: S35 - S42CrossRefGoogle Scholar
  8. 8.
    Chambers HF (1995) In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP2a. Antimicrob Agents Chemother 39: 462–466PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ford CW, Hamel JC, Wilson DM et al (1996) In vivo activities of U-100592 and U100766, novel oxazolidinone antimicrobial agents against experimental bacterial infections. Antimicrob Agents Chemother 40: 2820–2823Google Scholar
  10. 10.
    Arthur M, Reynolds P, Courvalin P (1996) Glycopeptide resistance in enterococci. Trends Microbiol 4: 401–407PubMedCrossRefGoogle Scholar
  11. 11.
    Woodford N, Johnson AP, Morrison D, Speller DC (1995) Current perspectives on glycopeptide resistance. Clin Microbiol Rev. 8: 585–615PubMedCentralPubMedGoogle Scholar
  12. 12.
    Linden PK (1997) Quinupristin/dalfopristin: a new therapeutic alternative for the treatment of vancomycin-resistant Enterococcus faecium and other serious Gram-positive infections. Todays Ther Trends 15 (2): 137–153Google Scholar
  13. 13.
    Nichols RL (1999) Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 44: 19–23PubMedCrossRefGoogle Scholar
  14. 14.
    Fagon J, Patrick H (2000) Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 161: 753–762Google Scholar
  15. 15.
    Moellering RC, Linden PK, Reinhardt J et al (1999) The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin–resistant Enterococcus faecium. J Antimicrob Chemother 44: 251–261PubMedCrossRefGoogle Scholar
  16. 16.
    Rubinstein E, Prokocimer P, Talbot GH (1999) Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 44: 37–46PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2001

Authors and Affiliations

  • A. R. De Gaudio

There are no affiliations available

Personalised recommendations